Lv11
70 积分 2022-07-01 加入
Hepatocellular carcinoma
2小时前
待确认
多层螺旋CT在结肠癌术前诊断和分期中的价值分析
5个月前
已关闭
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
5个月前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
5个月前
已完结
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
5个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
5个月前
已完结
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
5个月前
已完结
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
5个月前
已完结
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
5个月前
已完结
皖公网安备34019202002308
